Research Program Funding. 3.1.1 Pfizer will fund the research to be performed by Rigel, pursuant to the Agreement, according to the following schedule: COMMITMENT YEAR ANNUAL COMMITMENT 1 $2,350,000.00 2 $2,350,000.00 The funding payments of two million three hundred and fifty thousand dollars ($2,350,000.00) shall support the work of the equivalent of ten (10) full time employees ("FTEs") of Rigel.
Research Program Funding. During the period commencing on the Effective Date and continuing until the expiration of the Term, Lilly shall pay ImmunoGen the FTE Cost for the conduct of ImmunoGen Activities on a quarterly basis in arrears. Within [***] days following the last day of each Calendar Quarter during the Term, ImmunoGen shall provide a report and invoice setting forth the aggregate number of hours devoted by ImmunoGen employees in performing ImmunoGen Activities during such Calendar Quarter [***]. Within [***] days from the date of its receipt of each such invoice, Lilly will pay to ImmunoGen the invoice amount due as reimbursement for the ImmunoGen Activities in accordance with Section 5.3 hereof. If Lilly disputes any charge contained in an invoice, it will pay any undisputed amount in accordance with the preceding sentence, and the disputed amount will be addressed under the dispute resolution provisions of Section 11.12 hereof. Portions of this Exhibit, indicated by the xxxx “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
Research Program Funding. In consideration for Vertex’s performance of its obligations under the Research Program (including its FTE staffing obligations pursuant to Section 2.3), upon the terms and conditions contained herein, Merck shall pay Vertex:
Research Program Funding. In consideration for its performance of the Research Program, Pfizer will pay Xenogen Cranbury up to Nine Million Dollars ($9,000,000) upon receipt of invoice from Xenogen Cranbury, payable as follows: Within thirty (30) days of the execution of this Agreement, a fee of One Million Dollars ($1,000,000) to be utilized for staffing, administrative and equipment acquisition costs over and above normal on going expenses. Within thirty days of the execution of the Agreement, a fee of One Million Dollars ($1,000,000) to be utilized for Start-UP Costs. On the first business day of each calendar quarter during the first and second years of this Agreement, a payment of [***] against Xenogen Cranbury’s invoice for such calendar quarter work to be performed and costs to be incurred in such calendar quarter; On the first business day of each calendar quarter during the third year of this Agreement, a payment of [***] against Xenogen Cranbury’s invoice for such calendar quarter work to be performed and costs to be incurred in such calendar quarter; During the third year of this Agreement, payments aggregating up to [***] in equal *** CONFIDENTIAL TREATMENT REQUESTED quarterly installments, due on the first business day of each quarter, against Pfizer’s receipt from Xenogen Cranbury during that year of quarterly reports containing Results achieved pursuant to the Research Plan, including detailed data regarding the phenotypic analysis of Transgenic Animals and Xenogen Cranbury’s invoice for such report; and
Research Program Funding. During the Research Program Term, Fuso agrees to spend an aggregate of one million dollars ($1,000,000) per year on funding for the Research Program.
Research Program Funding. Dainippon shall support RiboGene's costs of conducting the Research Program by making research payments as follows: Due Date Amount -------- ------ Signing of this Agreement US$2,000,000 First Anniversary of this Agreement US$2,000,000 Second Anniversary of this Agreement US$2,000,000 RiboGene shall provide Dainippon with a statement of the details of RiboGene's estimated costs of conducting the Research Program prior to the above payment by Dainippon and quarterly reports describing actual costs and expenses actually incurred at RiboGene. Any costs incurred by RiboGene during the Tail End Period for conducting research activities assigned to it by the Research Committee will be reimbursed by Dainippon. If an installment of the Research Program Funding would have become due on a date after Dainippon gives notice of termination of this Agreement pursuant to Section 11.2, then on such date Dainippon shall pay only such portion of the installment as shall apply to the remaining period of the Research Term which will occur after such date. If any amount of the Research Program Funding already paid by Dainippon hereunder is not used for the Research Program upon termination of this Agreement except for material breach by Dainippon, such unused amount shall be refunded to Dainippon.
Research Program Funding. Juno shall make the following payments to Editas for the research to be conducted under the Research Program: (a) within [**] days after the first day of each [**] month period during the Research Program Term, an amount equal to [**] FTEs, or such other number of FTEs to be devoted by Editas to the conduct of the Research Program and paid for by Juno during such [**] month period as the Parties may have agreed and provided in the Research Plan, as such number may have been increased or decreased in accordance with Section 2.4, multiplied by the FTE Rate; and (b) the costs of one-time specialized reagents, the identity and costs for which are as identified in the Research Plan, not to exceed [**] dollars ($[**]) unless otherwise agreed by the Parties and provided in the Research Plan, within [**] days after presentation of an invoice therefor. In the event that the number of FTEs devoted by Editas to the conduct of the Research Program is adjusted in accordance with Section 2.4 during any [**] month period during the Research Program Term so that such number is more or less than the forecasted number of FTEs on which Juno’s payment for such [**] month period was based under Section 6.2(a), then the following shall apply: (1) in the event such number is less than the forecasted number and results in an overpayment by Juno, Juno may deduct the amount of such overpayment from any future amounts payable to Editas under Section 6.2(a), provided that if no further payments are due under Section 6.2(a), Editas shall refund such overpayment within [**] days after presentation of an invoice therefor; and (2) in the event such number is more than the forecasted number and results in an underpayment by Juno, Juno shall pay such additional amounts to cure such underpayment within [**] days after presentation of an invoice therefor.
Research Program Funding. In consideration for its performance of the ------------------------- Research Program, Pfizer will pay Xenogen Cranbury up to Nine Million Dollars ($9,000,000) upon receipt of invoice from Xenogen Cranbury, payable as follows:
Research Program Funding. Amgen shall fund and Array shall conduct the Research Program(s) at the following effort levels ("Funding Commitment"):
Research Program Funding. In consideration for its performance of the Research Program, Pfizer will pay Xenogen Cranbury a total of [***] upon receipt of invoices from Xenogen Cranbury, payable as follows:
